Lakewood-Amedex Biotherapeutics Reports 2026 Annual Meeting Vote Results

What Happened Lakewood-Amedex Biotherapeutics Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on September 22, 2026 (record date July 30, 2026). There were 2,369,688 shares outstanding and entitled to vote. All director nominees were elected and shareholders approved several corporate actions, including an increase in authorized common stock, authority for a reverse stock split (up to 1-for-20), an increase to the company’s equity incentive plan, and the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm.

Key Details

• Director elections: Kelvin Cooper, Ph.D. (For 974,809; Withhold 294,767; Broker non-vote 44,473); Doug Manion, M.D., FRCP (C) (For 976,025; Withhold 293,551; Broker non-vote 44,473); Leonard J. DeRoma (For 938,954; Withhold 330,622; Broker non-vote 44,473); Joseph Tucker, Ph.D. (For 975,720; Withhold 293,856; Broker non-vote 44,473).
• Authorized shares increased: shareholders approved amending the articles to raise authorized common stock from 12,500,000 to 100,000,000 (vote: For 927,022; Against 341,843; Abstain 711; Broker non-votes 44,473).
• Reverse split authority: shareholders authorized the Board to effect one or more reverse stock splits at a cumulative ratio up to 1-for-20 (vote: For 922,614; Against 333,546; Abstain 13,416; Broker non-votes 44,473).
• Equity plan amendment: shareholders approved increasing the 2020 Equity Incentive Plan share reserve to 400,000 shares (vote: For 951,373; Against 317,012; Abstain 1,191; Broker non-votes 44,473).
• Auditor ratification: CBIZ CPAs P.C. was ratified as the independent registered public accounting firm (vote: For 1,041,961; Against 33,322; Abstain 238).

Why It Matters

• The large increase in authorized shares (to 100 million) gives the company capacity to issue more common stock for financing, acquisitions or other corporate purposes — a potential source of future dilution depending on how shares are used.
• The Board now has the flexibility to implement a reverse stock split (up to 1-for-20), which can reduce the number of outstanding shares and affect the stock price per share and listing requirements if executed.
• Increasing the equity plan reserve to 400,000 shares enables additional stock-based compensation for employees and directors, which can impact future share issuance.
• Ratification of CBIZ CPAs P.C. confirms continuity of the company’s independent auditor.

Investors should watch for any subsequent filings (e.g., certificate of amendment or Form 8-K announcing a reverse split implementation) that would provide timing and further details.